

Result Update – Q4FY26 || Current Market Price – INR 1,007 || Target Price – INR 1,344 || Upside – 33.5% || Date: 18th May 2026

Multiple Growth Engines Entering Inflection Phase

Investment thesis:

India Category Development Engine Emerging as Core Value Driver: GCPL's India business is structurally transitioning from a legacy soaps and insecticides franchise into a diversified Home & Personal Care platform, with the "Goodness Manifesto" strategy now delivering visible outcomes after 3+ years of execution. Q4 FY26 marked a clear inflection, with standalone UVG at 8%, revenue growth at 10%, and EBITDA growth at 18%, driven by broad-based category momentum. Household Insecticides is witnessing a structural recovery post the RNF rollout, while Fabric Care, Air Fresheners, and Perfumes continue to scale rapidly, benefiting from low penetration and premiumization trends. Importantly, Home Care now contributes ~47% of standalone India revenue versus ~40% two years ago, structurally improving growth quality, pricing power, and margin resilience.

Inflationary Environment Strengthening Organized Player Advantage: The current crude-led inflation cycle is likely to favor organized FMCG players like GCPL despite near-term margin pressure. Broad-based inflation enables industry-wide price hikes, while local and unorganized players remain disproportionately impacted due to weaker procurement scale and higher logistics sensitivity. GCPL has already implemented pricing increases across soaps, detergents, and HI from April 2026, with benefits expected from Q1 FY27 onwards. Management remains focused on protecting absolute EBITDA while prioritizing market share gains, consistent with the strategy adopted during prior inflationary cycles.

Indonesia Recovery Turning into Multi-Quarter Earnings Catalyst: Indonesia, which contributes ~13% of consolidated revenue, is showing signs of recovery after multiple weak quarters driven by competitive pricing pressure. The business has now delivered two consecutive quarters of 4% UVG, indicating stabilization in demand and competitive intensity. Management highlighted improving traction for the Stella LV relaunch, while potential IDR stabilization could turn prior currency headwinds into a tailwind. A sustained recovery could materially improve consolidated profitability over FY27-28.

Africa FMCG Expansion Offers Long-Duration Optionality: GCPL's Africa business is gradually transitioning from a hair-fashion-led franchise into a broader FMCG platform, creating meaningful long-term optionality. Q4 FY26 revenue grew 20%, though profitability remained subdued due to elevated investments behind emerging FMCG categories such as Aer Pocket. Hair Fashion continues to remain a strong cash-generating business, while newer categories are scaling across African markets through India-led manufacturing and exports. Successful execution could unlock a meaningful incremental growth driver over the medium term.

Outlook - GCPL appears well-positioned for a multi-year earnings re-rating, supported by accelerating India category expansion, improving mix toward higher-margin Home Care, and early signs of recovery in Indonesia. While near-term commodity inflation may pressure margins, the environment structurally favors organized players with pricing power and scale advantages. Simultaneously, Africa offers long-duration optionality through FMCG expansion. Overall, growth quality is improving materially, with multiple earnings drivers emerging concurrently.


Valuation – On this backdrop we expect Godrej Consumer Products to deliver a Revenue/EBITDA/PAT CAGR of 11%/14%/21% over FY26-FY28E, which translates the stock trading at 39x FY28E. We value the stock at 52x FY28E, implying a target price of INR 1,344. An upside of 33.5%. Rating: **BUY**

Key Risk – (a) Sustained Brent crude above USD 110/bbl could materially delay margin recovery and compress EBITDA margins across key categories. (b) Aggressive competitive pricing in soaps by larger FMCG peers could intensify margin pressure in Personal Wash, which contributes ~25% of standalone revenue. (c) Currency volatility across key international markets, particularly Indonesia and Africa, could significantly impact consolidated earnings and profitability.

Particulars	
CMP (INR)	1,007
Market Cap (Cr)	1,02,882
Free Float Market Cap (Cr)	38,716
52 Week High / Low (INR)	1,308 / 967
Avg Daily Vol (1Y) shares	14,36,152
No. of Shares (Cr.)	102

Key Financial (INR Cr.)	FY26	FY27E	FY28E
Net Revenue	15,178	17,119	18,755
EBITDA	3,156	3,595	4,075
PAT	1,861	2,408	2,745
EPS	18.2	23.5	25.9

Holding	Sep-25	Dec-25	Mar-26
Promoters	53.07	53.06	53.06
FIIIs	18.23	15.41	13.94
DIIIs	13.58	15.41	13.94
Public	15.11	15.06	14.99
Total	100.0	100.0	100.0



Source: Company Research, Deven Choksey Research

Story in Charts

Exhibit 1: Revenue Growth driven by all fronts




Exhibit 2: Gross Profit and GP Margin




Exhibit 3: EBITDA & EBITDA Margin





Exhibit 4: PAT & EPS



Source: Company Research, Deven Choksey Research

Result Snapshot

Particulars (₹ Cr)	Q4 FY25	Q3 FY26	Q4 FY26	QoQ %	YoY %
Revenue from Operations	3,514	3,998	3,900	-2.4%	+11.0%
Sale of Products	3,494	3,978	3,885	-2.3%	+11.2%
Other Operating Revenue	20	20	16	-20.0%	-20.0%
Other Income	74	56	69	+23.2%	-6.8%
Total Income	3,588	4,054	3,970	-2.1%	+10.6%
EXPENSES					
Raw Material + Packing Cost	1,443	1,397	1,435	+2.7%	-0.6%
Purchase of Stock-in-Trade	237	448	416	-7.1%	+75.5%
Change in Inventories	29	87	19	-78.2%	-34.5%
Total Material Cost	1,709	1,932	1,870	-3.2%	+9.4%
Material Cost % of Revenue	48.6%	48.3%	47.9%	-40bps	-70bps
Employee Benefits	262	328	325	-0.9%	+23.8%
Ad & Publicity (Restated)	281	306	274	-10.5%	-2.5%
Other Expenses (Restated)	503	552	590	+6.9%	+17.3%
Finance Cost	90	79	90	+13.9%	+0.8%
Depreciation & Amortization	73	66	76	+15.2%	+4.1%
Total Expenses	2,917	3,263	3,225	-1.2%	+10.6%
KEY PROFITABILITY					
Gross Profit	1,805	2,066	2,031	-1.7%	+12.5%
Gross Margin %	51.4%	51.7%	52.1%	+40bps	+70bps
EBITDA	759	880	841	-4.4%	+10.8%
EBITDA Margin %	21.6%	22.0%	21.6%	-40bps	Flat
Profit Before Tax	639	700	651	-7.0%	+1.9%
Tax Expense	228	202	200	-1.0%	-12.3%
Tax Rate %	35.6%	28.9%	30.7%	+180bps	-490bps
Reported PAT	412	498	452	-9.2%	+9.7%
EPS (₹)	4.03	4.87	4.42	-9.2%	+9.7%

Source: Company Research, Deven Choksey Research

Key Concall Highlights

Margin Outlook – Near-term Headwinds, Medium-term Confidence

- Management guided for Q1-Q2 FY27 margin pressure with Brent at USD 100-110/bbl and palm (CPO) at 4,500-4,800 MYR, translating to 7-9% blended raw material cost inflation.
- Key difference from prior cycles: crude-led inflation affects ALL categories (unlike palm which hits only soaps), making it easier to pass through via calibrated price hikes across the portfolio.
- Price hikes already implemented in April 2026: Soaps +5%, Detergents +6-7%, Household Insecticides +4-5%. These are NOT reflected in Q4FY26 numbers.
- Management expects margin recovery within 3-4 months if crude holds at USD 100-110 (unlike palm crises which take longer to recover).
- Strategy: Accept lower percentage margins in the near-term but drive higher revenue growth and protect absolute EBITDA. Locals/unorganized players face disproportionate pressure.

Volume vs. Pricing Dynamics

- FY27 outlook: Volumes may be slightly lower than originally planned at the start of the year, but revenue growth will be higher due to pricing. EBITDA expected to be reasonably good or at current levels.
- No expectation of volume dry-up from price hikes. In crude-led inflation, organized players gain share vs. local/unorganized players.
- Excluding soaps, India volume growth is in double-digits, making GCPL one of the volume growth leaders in Indian FMCG.

Category-Specific Insights

- Household Insecticides: RNF strategy working; converting a zero-to-low single digit growth category to high single digit, potentially compounding to double digits over time. Structural HI issues of the last decade appear to be behind.
- Soaps: Volume muted partly due to temperature anomalies and still-elevated grammage base effects (e.g., Godrej No.1 INR 10 pack went from 55g to 40g, now back to ~46-47g, still 15-20% below YoY). Pricing tailwinds expected in FY27. Expanding into skin cleansing beyond soaps (Cinthol body wash, Magic hand wash, Muuchstac face wash).
- Fabric Care (Godrej Fab): Robust double-digit growth momentum, market share gains continuing. In detergents, company follows competitor pricing (not a market leader).
- Air Fresheners: Explosive growth globally; production in India and exported. Will become a visible contributor going forward.
- Perfumes & Deodorants: Strong double-digit growth; KS99 now scaled pan-India.

Revenue Reclassification – Accounting Change (EAC/ICAI)

- GCPL has reclassified certain customer-related promotional spends (in-store visibility, display arrangements, mailers) from operating expenses to a deduction from revenue, aligning with the ICAI Expert Advisory Committee opinion published in February 2026.
- Impact: Revenue appears lower (net-down), reported EBITDA margin appears higher (by ~50-70bps). NO impact on absolute EBITDA, PAT, EPS, or total equity.
- Comparatives have been restated. FY25 consolidated revenue restated from INR14,364 Cr to INR13,997 Cr. Key implication: YoY growth rates remain largely unchanged; this is a presentational change, not an economic one.

Other Key Takeaways

- Dividend: INR 5/share (500% on FV INR 1) interim dividend declared for FY27. Record date: May 12, 2026.
- Tax rate: ETR expected to remain stable in FY27.
- Board changes: Nadir Godrej to retire as Non-Executive Director on August 7, 2026 (attaining age 75).
- Analyst/Investor Day: Scheduled for May 11, 2026 at GCPL headquarters, with deep dives on strategy, category development, and growth roadmap.

Key Financials

Income Statement (Cr.)	FY25A	FY26A	FY27E	FY28E
Revenues	13,997	15,178	17,119	18,755
COGS	6,536	7,394	7,782	8,710
Gross profit	7,460	7,783	9,337	10,044
Employee cost	1,149	1,232	1,337	1,465
Other expenses	3,309	3,395	4,405	4,505
EBITDA	3,003	3,156	3,595	4,075
EBITDA Margin	21.5%	20.8%	21.0%	21.7%
D&A	234	268	292	321
EBIT	2,769	2,888	3,303	3,754
Interest expense	350	332	315	310
Other income	316	266	266	266
PBT	2,735	2,823	3,254	3,710
Tax	820	729	846	964
Exceptional items	(63)	(233)	0	0
PAT	1,852	1,861	2,408	2,745
EPS (INR)	18.1	18.2	23.5	25.9

Balance Sheet (Cr.)	FY25A	FY26A	FY27E	FY28E
Equity				
Equity Capital	102	102	102	102
Other Equity	11,902	12,551	13,259	14,255
Total Equity	12,004	12,653	13,361	14,357
Non-Current Liabilities				
Borrowings	0	0	0	0
Provisions	149	150	150	150
Lease Liabilities	92	218	232	251
Other Non-Current Liabilities	493	606	606	606
Total Non-Current Liabilities	734	973	988	1,007
Current Liabilities				
Borrowings	3,883	4,136	4,000	3,995
Lease Liabilities	30	62	85	98
Provisions	107	135	135	135
Trade Payables	2,142	2,302	2,490	2,787
Other current liabilities	772	1,072	1,072	1,072
Total Current Liabilities	6,934	7,707	7,782	8,087
Total Equity & Liabilities	19,672	21,334	22,131	23,452
Non-Current Assets				
PPE	1,229	1,878	2,122	2,410
Goodwill	5,145	5,715	5,715	5,715
Other current assets	5,959	6,695	7,852	8,652
Total Non-Current Assets	12,334	14,289	15,689	16,777
Current Assets				
Inventories	1,419	1,659	1,712	1,916
Trade Receivables	1,819	1,837	2,120	2,352
Investments	3,103	1,852	1,756	1,700
Cash and Bank	455	977	259	111
Other current assets	543	595	595	595
Total Current Assets	7,338	7,045	6,442	6,675
Total Assets	19,672	21,334	22,131	23,452

Source: Company Research, Deven Choksey Research

Godrej Consumer Products Ltd.			
Date	CMP (INR)	TP (INR)	Recommendation
18-May-26	1,007	1,344	BUY
26-Aug-25	1,259	1,433	ACCUMULATE
08-May-25	1,237	1,332	ACCUMULATE
27-Jan-25	1,130	1,264	ACCUMULATE
28-Oct-25	1,292	1,452	ACCUMULATE
21-Aug-24	1,394	1,541	ACCUMULATE
09-May-24	1,330	1,426	ACCUMULATE

Rating Legend (Expected over a 12-month period)	
Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

ANALYST CERTIFICATION:

I, **Neel Mehta**, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While I would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily, and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

I submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Neel Mehta** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Neel Mehta**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and or its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restrictions.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

- Please send your feedback to research.retail@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number - U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058